These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25850038)

  • 1. IDO inhibitors move center stage in immuno-oncology.
    Sheridan C
    Nat Biotechnol; 2015 Apr; 33(4):321-2. PubMed ID: 25850038
    [No Abstract]   [Full Text] [Related]  

  • 2. Marrying immunotherapy with chemotherapy: why say IDO?
    Muller AJ; Prendergast GC
    Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
    Yentz S; Smith D
    BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
    Munn DH
    Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
    Brochez L; Chevolet I; Kruse V
    Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
    Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
    Front Immunol; 2021; 12():789473. PubMed ID: 34938297
    [No Abstract]   [Full Text] [Related]  

  • 7. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
    Selvan SR; Dowling JP; Kelly WK; Lin J
    Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).
    Dolušić E; Frédérick R
    Expert Opin Ther Pat; 2013 Oct; 23(10):1367-81. PubMed ID: 23992582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors.
    Jernigan FE; Sun L
    Future Med Chem; 2017 Aug; 9(12):1309-1311. PubMed ID: 28771034
    [No Abstract]   [Full Text] [Related]  

  • 10. Research progress of indoleamine 2,3-dioxygenase inhibitors.
    Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
    Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
    Muller AJ; Malachowski WP; Prendergast GC
    Expert Opin Ther Targets; 2005 Aug; 9(4):831-49. PubMed ID: 16083346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
    Eleftheriadis T
    Front Immunol; 2018; 9():1879. PubMed ID: 30150994
    [No Abstract]   [Full Text] [Related]  

  • 13. ASCO Reveals Additional Promising Results With Immunotherapies.
    Brower V
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26424738
    [No Abstract]   [Full Text] [Related]  

  • 14. Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
    Zhu MMT; Dancsok AR; Nielsen TO
    Curr Oncol Rep; 2019 Jan; 21(1):2. PubMed ID: 30659394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
    Löb S; Königsrainer A; Rammensee HG; Opelz G; Terness P
    Nat Rev Cancer; 2009 Jun; 9(6):445-52. PubMed ID: 19461669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.
    Ricciuti B; Leonardi GC; Puccetti P; Fallarino F; Bianconi V; Sahebkar A; Baglivo S; Chiari R; Pirro M
    Pharmacol Ther; 2019 Apr; 196():105-116. PubMed ID: 30521884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of IDO1 Inhibitors: From Bench to Bedside.
    Prendergast GC; Malachowski WP; DuHadaway JB; Muller AJ
    Cancer Res; 2017 Dec; 77(24):6795-6811. PubMed ID: 29247038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Companies Scaling Back IDO1 Inhibitor Trials.
    Cancer Discov; 2018 Jul; 8(7):OF5. PubMed ID: 29848606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule drugs with immunomodulatory effects in cancer.
    Murphy AG; Zheng L
    Hum Vaccin Immunother; 2015; 11(10):2463-8. PubMed ID: 26110550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Journal Honors Burles Johnson III, MD, PhD, As Recipient of the 2017 Journal of Clinical Oncology Young Investigator Award.
    J Clin Oncol; 2017 Aug; 35(22):2457-2458. PubMed ID: 28594598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.